Paratek Pharmaceuticals Inc (NASDAQ:PRTK) VP Adam Woodrow sold 2,659 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $8.96, for a total transaction of $23,824.64. Following the completion of the transaction, the vice president now owns 138,167 shares in the company, valued at $1,237,976.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Adam Woodrow also recently made the following trade(s):
- On Wednesday, October 3rd, Adam Woodrow sold 8,750 shares of Paratek Pharmaceuticals stock. The stock was sold at an average price of $9.82, for a total transaction of $85,925.00.
NASDAQ:PRTK traded down $0.33 during trading hours on Friday, hitting $7.45. 723,389 shares of the company traded hands, compared to its average volume of 826,785. The company has a current ratio of 11.39, a quick ratio of 7.88 and a debt-to-equity ratio of 3.97. Paratek Pharmaceuticals Inc has a one year low of $6.27 and a one year high of $22.00. The stock has a market cap of $245.43 million, a PE ratio of -2.26 and a beta of 0.74.
A number of brokerages recently issued reports on PRTK. BidaskClub upgraded shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 6th. Wedbush set a $20.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 19th. Bank of America initiated coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They set a “neutral” rating and a $13.00 price objective for the company. Finally, Guggenheim set a $26.00 price objective on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.29.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTK. Highland Capital Management LP raised its stake in shares of Paratek Pharmaceuticals by 99.9% during the 2nd quarter. Highland Capital Management LP now owns 1,917,878 shares of the specialty pharmaceutical company’s stock worth $19,562,000 after purchasing an additional 958,600 shares during the period. BlackRock Inc. raised its stake in Paratek Pharmaceuticals by 27.3% in the 2nd quarter. BlackRock Inc. now owns 2,583,390 shares of the specialty pharmaceutical company’s stock valued at $26,350,000 after acquiring an additional 554,545 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Paratek Pharmaceuticals in the 2nd quarter valued at about $3,629,000. Granahan Investment Management Inc. MA purchased a new position in Paratek Pharmaceuticals during the 2nd quarter valued at about $1,801,000. Finally, California Public Employees Retirement System purchased a new position in Paratek Pharmaceuticals during the 1st quarter valued at about $1,565,000. Institutional investors own 77.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Paratek Pharmaceuticals Inc (NASDAQ:PRTK) VP Sells 2,659 Shares of Stock” was published by BBNS and is owned by of BBNS. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/2018/11/10/paratek-pharmaceuticals-inc-prtk-vp-adam-woodrow-sells-2659-shares/2847529.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Recommended Story: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.